FDA approves 40 mg follow-on version of glatiramer acetate

Fármacos complejos no biológicos/ Novedades | Posted 09/03/2018 post-comment0 Post your comment

Sandoz, the generics division of Novartis, announced on 13 February 2018 the approval of its 40 mg follow-on version of glatiramer acetate by the US Food and Drug Administration (FDA).

NBCD ASEAN V16F09BF S69 V16F20JM

Glatopa (glatiramer acetate) 40 mg/mL is a fully substitutable, AP-rated generic version of the originator product, Teva Pharmaceutical’s (Teva) Copaxone (glatiramer acetate).

Copaxone is classified as a non-biological complex drug (NBCD), but since there are currently no guidelines for ‘follow-on’ versions of NBCDs such drugs are approved under the generics pathway. However, due to their complexity and the fact that they cannot be fully quantitated, characterized or described by (physico-)chemical analytical tools, some groups have said that the generics pathways may not be appropriate and have called for regulatory guidelines for follow-on versions of NBCDs [1]. The European Medicines Agency has responded to such concerns with the adoption of its first reflection paper for NBCDs in the form of follow-on versions of iron-based nano-colloidal products [2].

Sandoz’s three-times-a-week therapy for patients with relapsing forms of multiple sclerosis (MS), Glatopa, has been available in a 20 mg dosage since 2015 [3]. However, approval of the double dosage was put on hold in 2017 due to contamination issues. The newly approved 40 mg dosage is not expected to be launched before 2019. The approval comes as a result of Sandoz’s collaboration with fellow generics maker Momenta Pharmaceuticals (Momenta).

Rival generics maker Mylan also had a 40 mg follow-on version of glatiramer acetate approved by FDA in October 2017.

Related articles
Follow-on versions of glatiramer acetate in Russia and Europe

Rigorous approach used to approve a follow-on version of glatiramer acetate

References
1. GaBI Online - Generics and Biosimilars Initiative. Guidelines needed for follow-on versions of NBCDs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Mar 9]. Available from: www.gabionline.net/Reports/Guidelines-needed-for-follow-on-versions-of-NBCDs
2. GaBI Online - Generics and Biosimilars Initiative. EMA issues draft reflection paper for iron-based nano-colloidal products [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Mar 9]. Available from: www.gabionline.net/Guidelines/EMA-issues-draft-reflection-paper-for-iron-based-nano-colloidal-products
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves first follow-on version of glatiramer acetate [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Mar 9]. Available from: www.gabionline.net/Non-Biological-Complex-Drugs/News/FDA-approves-first-follow-on-version-of-glatiramer-acetate

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Sandoz, US FDA

comment icon Comments (0)
Post your comment
Related content
Mylan launches first follow-on glatiramer acetate in the UK
Multiple Sclerosis V14A24
Fármacos complejos no biológicos/ Novedades Posted 15/02/2018
Impax announces FDA approval of follow-on sevelamer carbonate
Nanoparticle V13J18
Fármacos complejos no biológicos/ Novedades Posted 17/11/2017
FDA approves follow-on version of sevelamer
99 AA010633
Fármacos complejos no biológicos/ Novedades Posted 30/06/2017
Warning letter causes delays for follow-on glatiramer acetate
Multiple Sclerosis V14A24
Fármacos complejos no biológicos/ Novedades Posted 17/03/2017
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010